Home Cart Sign in  
Chemical Structure| 67416-61-9 Chemical Structure| 67416-61-9

Structure of AKBA
CAS No.: 67416-61-9

Chemical Structure| 67416-61-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AKBA (Acetyl-11-keto-β-boswellic acid) is an active compound extracted from frankincense and a novel activator of Nrf2. AKBA can be used in research on inflammatory diseases and cancer.

Synonyms: Acetyl-11-keto-β-boswellic acid; 3-O-acetyl-11-keto-β-Boswellic acid; Acetylketo-β-boswellic acid

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AKBA

CAS No. :67416-61-9
Formula : C32H48O5
M.W : 512.72
SMILES Code : C[C@@]([C@@](C1=C2)(CC[C@@](C)(CC[C@H]3C)[C@@]1([H])[C@H]3C)C)(CC[C@@]4([H])[C@@]5(C)C(O)=O)[C@@](C2=O)([H])[C@]4(CC[C@H]5OC(C)=O)C
Synonyms :
Acetyl-11-keto-β-boswellic acid; 3-O-acetyl-11-keto-β-Boswellic acid; Acetylketo-β-boswellic acid
MDL No. :MFCD03788777
InChI Key :HMMGKOVEOFBCAU-BCDBGHSCSA-N
Pubchem ID :11168203

Safety of AKBA

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse primary keratinocytes 20 μM 12 h AKBA decreases H3K27me3 methylation level EBioMedicine. 2019 Jan;39:575-590
HaCaT cells 20 μM 12 h AKBA inhibits MAT2A function, decreases SAM level and SAM/SAH ratio EBioMedicine. 2019 Jan;39:575-590
U87-MG cells 10 mM, 20 mM, 30 mM 24 h To detect the inhibitory effect of AKBA on autophagy in U87-MG cells using transmission electron microscopy. Results showed that AKBA significantly inhibited autophagy in U87 cells. Acta Pharm Sin B. 2020 Feb;10(2):301-312
HEK293 cells 25 μM 180 min AKBA significantly increased the formation of 15-LOX products in cells expressing 15-LOX-1 and 15-LOX-2. Adv Sci (Weinh). 2023 Feb;10(6):e2205604
M2-MDMs 10 μM 180 min AKBA significantly increased the formation of 12/15-LOX-derived lipid mediators and SPMs, particularly in M2-MDMs. Adv Sci (Weinh). 2023 Feb;10(6):e2205604
Human monocytes 10 μM 90 min AKBA significantly elevated the levels of 15-LOX and 12-LOX products and increased the formation of SPMs, especially in M2-MDMs. Adv Sci (Weinh). 2023 Feb;10(6):e2205604
M1-like macrophages 10 μM 90 min AKBA significantly reduced the formation of LTB4 while increasing the production of 12-HETE. Nat Chem Biol. 2020 Jul;16(7):783-790
Neutrophils 10 μM 90 min AKBA significantly reduced the levels of 5-HETE and LTB4 while increasing the production of 12-HETE. Nat Chem Biol. 2020 Jul;16(7):783-790
HEK293 cells 25 μM 15 min AKBA significantly reduced the formation of 5-LOX products (e.g., 5-HETE and LTB4) while increasing the production of 12-HETE. Nat Chem Biol. 2020 Jul;16(7):783-790
Human prostate cancer cells (PC-3) 50μM AKBA inhibited PC-3 cell proliferation, requiring a higher concentration than that needed to suppress endothelial cell proliferation. Cancer Res. 2009 Jul 15;69(14):5893-900
Human umbilical vascular endothelial cells (HUVECs) 5-10 μM 6-8 h AKBA significantly suppressed or terminated VEGF-induced tubular formation of endothelial cells. Cancer Res. 2009 Jul 15;69(14):5893-900
Human umbilical vascular endothelial cells (HUVECs) 1-5 μM 24 h AKBA inhibited VEGF-induced HUVEC migration and invasion in a dose-dependent manner. Cancer Res. 2009 Jul 15;69(14):5893-900
U87-MG human glioblastoma cells 10, 20, 30 μM 24 and 48 h AKBA inhibited cell proliferation, caused the release of LDH, decreased DNA synthesis, and inhibited the migration, invasion, and colony formation of U87-MG human glioblastoma cells. J Exp Clin Cancer Res. 2018 Jul 3;37(1):132
U251 human glioblastoma cells 10, 20, 30 μM 24 and 48 h AKBA inhibited cell proliferation, caused the release of LDH, decreased DNA synthesis, and inhibited the migration, invasion, and colony formation of U251 human glioblastoma cells. J Exp Clin Cancer Res. 2018 Jul 3;37(1):132
PC3 cells 5, 10, 20, 30, 40 μM 48 h AKBA dose-dependently inhibited cell proliferation in PC3 cells, with an IC50 value of approximately 21μM. Acta Pharmacol Sin. 2019 May;40(5):689-698
PC3/Doc cells 5, 10, 20, 30, 40 μM 48 h AKBA dose-dependently inhibited cell proliferation and induced cell apoptosis in docetaxel-resistant PC3/Doc cells, with an IC50 value of approximately 17μM in anti-proliferation. Acta Pharmacol Sin. 2019 May;40(5):689-698
LS174T cells 20 μM 72 h AKBA inhibited growth of LS174T cells, resulting in a 40-50% reduction in cell numbers. Br J Pharmacol. 2006 Aug;148(8):1099-107
HT-29 cells 30 μM 72 h AKBA inhibited growth of HT-29 cells, resulting in a 40-50% reduction in cell numbers. Br J Pharmacol. 2006 Aug;148(8):1099-107
HCT-116 cells 5-25 μM 24-72 h AKBA inhibited cellular growth in a time- and dose-dependent manner in HCT-116 cells, leading to G1 phase cell cycle arrest accompanied by downregulation of cyclin D1, E, CDK2, CDK4, and phosphorylated Rb, and upregulation of p21 expression. Br J Pharmacol. 2006 Aug;148(8):1099-107
Schwann cells 2 µg/mL 0, 6, 12, 24 h AKBA treatment significantly increased p-ERK1/2 expression in a time-dependent manner. Neural Regen Res. 2018 Mar;13(3):484-491
Schwann cells 1.25, 2.5, 5, 10, 20 µg/mL 24 h AKBA significantly promoted SC proliferation at concentrations of 1.25–5 µg/mL, peaking at 2 µg/mL; inhibited proliferation at >5 µg/mL. Neural Regen Res. 2018 Mar;13(3):484-491

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice Orthotopic U87-MG glioblastoma model Oral administration 100 mg/kg, 200 mg/kg Once daily for 21 days To evaluate the anti-tumor effects of AKBA on orthotopic glioblastoma. MRI results showed that AKBA significantly inhibited tumor growth without obvious weight loss or abnormal behavior. Acta Pharm Sin B. 2020 Feb;10(2):301-312
BALB/c-nu nude mice U87-MG human glioblastoma xenograft model Oral 100 mg/kg Once daily for 14 days Oral administration of AKBA significantly suppressed the tumorigenicity of U87-MG cells in a xenograft mouse model. J Exp Clin Cancer Res. 2018 Jul 3;37(1):132
C57BL/6 mice RM-1/Doc homograft model Intraperitoneal injection 30 mg/kg Once daily for 14 days AKBA significantly suppressed the growth of RM-1/Doc homografts without decreasing body weight. Acta Pharmacol Sin. 2019 May;40(5):689-698
BALB/cA nude mice Human prostate tumor xenograft model Subcutaneous injection 10 mg/kg Once daily for 30 days AKBA significantly suppressed tumor volume and weight growth and inhibited tumor angiogenesis. Cancer Res. 2009 Jul 15;69(14):5893-900
Sprague-Dawley rats Sciatic nerve injury model Intraperitoneal injection 1.5, 3, 6 mg/kg Once every 2 days for 30 days 3 and 6 mg/kg AKBA significantly increased sciatic nerve index, Cuadros index of triceps muscle, p-ERK1/2 expression, and S100 immunoreactivity. Neural Regen Res. 2018 Mar;13(3):484-491
Mice Zymosan-induced peritonitis Intraperitoneal injection 20 mg/kg Single dose, lasting 24 hours AKBA significantly elevated SPM levels and promoted the resolution of inflammation. Adv Sci (Weinh). 2023 Feb;10(6):e2205604

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.95mL

0.39mL

0.20mL

9.75mL

1.95mL

0.98mL

19.50mL

3.90mL

1.95mL

References

[1]Rehman NU, Ali L, et al. Quantification of AKBA in Boswellia sacra Using NIRS Coupled with PLSR as an Alternative Method and Cross-Validation by HPLC. Phytochem Anal. 2017 Sep 7.

[2]Meka B, Ravada SR, et al. Synthesis of new analogs of AKBA and evaluation of their anti-inflammatory activities. Bioorg Med Chem. 2017 Feb 15;25(4):1374-1388.

[3]Takada Y, Ichikawa H, Badmaev V, Aggarwal BB. Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression. J Immunol. 2006 Mar 1;176(5):3127-40. doi: 10.4049/jimmunol.176.5.3127. PMID: 16493072.

[4]Park YS, Lee JH, Harwalkar JA, Bondar J, Safayhi H, Golubic M. Acetyl-11-keto-beta-boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the extracellular-signal regulated kinase 1 and 2. Adv Exp Med Biol. 2002;507:387-93. doi: 10.1007/978-1-4615-0193-0_60. PMID: 12664615.

[5]Hoernlein RF, Orlikowsky T, Zehrer C, Niethammer D, Sailer ER, Simmet T, Dannecker GE, Ammon HP. Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. J Pharmacol Exp Ther. 1999 Feb;288(2):613-9. PMID: 9918566.

[6]Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, Liu M. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res. 2009 Jul 15;69(14):5893-900. doi: 10.1158/0008-5472.CAN-09-0755. Epub 2009 Jun 30. PMID: 19567671; PMCID: PMC2724674.

[7]Park YS, Lee JH, Bondar J, Harwalkar JA, Safayhi H, Golubic M. Cytotoxic action of acetyl-11-keto-beta-boswellic acid (AKBA) on meningioma cells. Planta Med. 2002 May;68(5):397-401. doi: 10.1055/s-2002-32090. PMID: 12058313.

 

Historical Records

Categories